Crucell to cancel West Nile vaccine programme
AMSTERDAM, Feb 12 (Reuters) - Dutch biotechnology firm Crucell (CRCL.AS: Quote, Profile, Research, Stock Buzz) (CRXL.O: Quote, Profile, Research, Stock Buzz) said on Tuesday it would discontinue its programme to develop a vaccine and human monoclonal antibodies for therapeutic use against West Nile.
"Crucell has come to the conclusion that the commercial and market opportunities for its West Nile products are not as attractive as other products in Crucell's pipeline," the company said in a statement.
Crucell also said to further postpone the registration submission of the Yellow Fever vaccine, called Flavimum, in Switzerland.
Crucell said it would focus on its MoRuViraten vaccine for Measles/Rubella, which is produced in the same facility as Flavimun. (Reporting by Harro ten Wolde)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Healthcare Collections
Details: ...hire position as a healthcare collector. It is...strong background in healthcare collection or hospital...understanding of healthcare billing guidelines...
Medical & Healthcare Opportunities
Details: ...in life. Medical / Healthcare Some of the opportunities...in the Medical and Healthcare area include: Dental...
Columbus - Healthcare Claims Examiners, Billers, and Coders
Details: ...immediate openings in Columbus and the surrounding areas for Healthcare Claims Examiners, Billers, and Coders as well as other insurance...
Revenue Cycle Management/ Healthcare
Details: ...process of building a robust Healthcare Revenue Cycle Practice, is...opportunity to the experienced Healthcare Revenue Cycle Management consultancy...
7 years after
Monkey waiters in Japan
